Renal Cell Carcinoma
From the Journals
RFS failed as endpoint in adjuvant immunotherapy trials
“Our meta-analysis failed to find a significantly strong association between RFS and OS in RCTs of adjuvant immunotherapy,” the authors concluded...
From the Journals
Short bursts of activity may cut cancer risk
Examples of such activity are vigorous housework, carrying heavy shopping bags around the grocery store, bursts of power walking, and playing high...
From the Journals
No benefit to adding limited radiation in advanced cancer
Median overall survival was not significantly better with radiotherapy, compared with the control group, nor was the objective response rate.
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.